Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.

Cancer research - 2 Oct 2023

Gou Xuxu, Kim Beom-Jun, Anurag Meenakshi, Lei Jonathan T, Young Meggie N, Holt Matthew V, Fandino Diana, Vollert Craig T, Singh Purba, Alzubi Mohammad A, Malovannaya Anna, Dobrolecki Lacey E, Lewis Michael T, Li Shunqiang, Foulds Charles E, Ellis Matthew J

Abstract excerpt

Transcriptionally active ESR1 fusions (ESR1-TAF) are a potent cause of breast cancer endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C-terminal estrogen/anti-estrogen-binding domain is replaced with translocated in-frame partner gene sequences that confer constitutive transactivation. To discover alternative treatments, a mass spectrometry (MS)-based kinase inhibitor pulldown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Estrogen Receptor alpha

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37071495
DOI: 10.1158/0008-5472.CAN-22-3484
PMCID: PMC10543968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.PMID 37071495Read ↗

<i>ESR1</i> fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesSemantic proximity Read ↗

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read ↗

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerSemantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Unveiling ESR1's Network Centrality Through Multi-Omics Fusion and AI: Implications for Next-Generation Endocrine TherapiesSemantic proximity Read ↗

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.Semantic proximity Read ↗

<i>ESR1</i> mutant breast cancers show elevated basal cytokeratins and immune activationSemantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.